Spyre Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 63.18 million compared to USD 18.82 million a year ago. Basic loss per share from continuing operations was USD 4.05 compared to USD 5 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
24.23 USD | +0.54% | -4.72% | +12.59% |
Jun. 24 | Spyre Therapeutics, Inc.(NasdaqGS:SYRE) added to S&P Biotechnology Select Industry Index | CI |
Jun. 18 | Spyre Therapeutics, Inc. Announces First Participants Dose in Phase 1 Trial of SPY001 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.59% | 1.22B | |
+16.73% | 121B | |
+21.13% | 114B | |
+18.05% | 23.61B | |
-17.94% | 20.43B | |
-16.24% | 16.55B | |
-11.76% | 16.45B | |
-44.45% | 15.59B | |
+69.92% | 15.19B | |
+1.41% | 13.54B |
- Stock Market
- Equities
- SYRE Stock
- News Spyre Therapeutics, Inc.
- Spyre Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023